WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Ohio Living
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Lygos Inc | July 26, 2022
Lygos Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International Inc. a developer and manufacturer of biodegradable products, today announced that FSI has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 25, 2022 in connection with its proposed merger with Lygos. On April 18, 2022, Lygos and FSI announced a definitive merger agreement in an all-stock transaction ...
Genetic Engineering and Biotechnology News | January 28, 2020
MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....
MedTech
Aesthetics Biomedical® Inc. | October 07, 2021
Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts...
Labiotech | January 15, 2020
The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...
Article
AI, Industrial Impact
Video
Industrial Impact, Medical
Cell and Gene Therapy, Industrial Impact
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE